Other therapy for short bowel syndrome

Omeprazole may be useful in patients with short bowel syndrome who have a high-output state, particularly in the first few months after surgery, when there may be gastric hypersecretion. In adults, use:

In some patients, high-dose therapy with omeprazole is required—patients may require up to 80 mg of omeprazole twice daily.

Antisecretory therapy using somatostatin analogues (eg octreotide, lanreotide) may be used by gastroenterologists in selected patients to reduce gastrointestinal fluid secretion, which decreases stoma fluid and electrolyte output.

Intestinotrophic therapy using teduglutide may be used by gastroenterologists in patients who are stable on home parenteral nutrition. The aim of intestinotrophic therapy is to wean parenteral nutrition requirements. In some cases, this allows patients to achieve enteral autonomy.